Therefore, researchers are exploring predictive biomarkers of ICI response, e.g., PD-L1 expression, tumor mutational burden (TMB)5–7, tumor immune phenotype8, somatic genomic features9, and the gut microbiome10. The gene discussed is CD274; the disease is neoplasm.